{"disease":{"id":"osteoporosis","name":"Osteoporosis","therapeutic_area":"Metabolic & Endocrinology","data":{"aiSummary":"The treatment landscape for osteoporosis primarily involves antiresorptive agents like bisphosphonates (e.g., risedronate, alendronate) and denosumab, which reduce bone loss. Anabolic agents, such as teriparatide and romosozumab, are also used to stimulate bone formation, particularly in high-risk patients. Recent advances include the development of new anabolic agents and biosimilars, offering alternative treatment options. The pipeline includes long-acting PTH analogs and other novel agents. The focus remains on early diagnosis, fracture risk assessment, and personalized treatment strategies to improve patient outcomes and reduce fracture incidence.","drug_count":10,"description":"Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and a consequent increase in fracture risk. The primary cause is an imbalance between bone resorption and bone formation, often exacerbated by hormonal changes, nutritional deficiencies, and certain medications. This results in weakened bones that are more susceptible to fractures, particularly in the hip, spine, and wrist.","subtype_count":11},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.953Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":24,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"denosumab","indication_name":"Drug-induced osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prolia","generic_name":"DENOSUMAB","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Tumor necrosis factor ligand superfamily member 11","drug_class":"RANK Ligand Inhibitor [EPC]","quality_score":60,"revenue":"6100","mechanism":"Prolia works by blocking a protein that breaks down bone."},{"drug_id":"denosumab","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prolia","generic_name":"DENOSUMAB","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Tumor necrosis factor ligand superfamily member 11","drug_class":"RANK Ligand Inhibitor [EPC]","quality_score":60,"revenue":"6100","mechanism":"Prolia works by blocking a protein that breaks down bone."},{"drug_id":"denosumab","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prolia","generic_name":"DENOSUMAB","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Tumor necrosis factor ligand superfamily member 11","drug_class":"RANK Ligand Inhibitor [EPC]","quality_score":60,"revenue":"6100","mechanism":"Prolia works by blocking a protein that breaks down bone."},{"drug_id":"calcium-phosphate","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricalcium Phosphate","generic_name":"calcium phosphate","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"calcium phosphate","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"ipriflavone","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Osten","generic_name":"IPRIFLAVONE","company_name":"","drug_phase":"phase_2","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"ipriflavone","quality_score":31,"revenue":null,"mechanism":"Osten works by inhibiting the sodium-dependent noradrenaline transporter, which helps to regulate bone metabolism."},{"drug_id":"calcitonin-pork-natural","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcitonin Pig","generic_name":"calcitonin (pork natural)","company_name":"","drug_phase":"unknown","molecular_target":"Amylin receptor AMY2, Calcitonin receptor, Amylin receptor AMY1","drug_class":"calcitonin (pork natural)","quality_score":null,"revenue":null,"mechanism":"Calcitonin Pig works by mimicking a hormone in the body that helps regulate calcium levels."},{"drug_id":"risedronate","indication_name":"Glucocorticoid Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risedronate","company_name":"Toronto Rehabilitation Institute","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"risedronate","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risedronate","company_name":"Toronto Rehabilitation Institute","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"risedronate","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risedronate","company_name":"Toronto Rehabilitation Institute","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"risedronate","indication_name":"Prevention of Glucocorticoid-Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risedronate","company_name":"Toronto Rehabilitation Institute","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"magnesium-oxide","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prepopik","generic_name":"MAGNESIUM OXIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"magnesium oxide","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"magnesium-oxide","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prepopik","generic_name":"MAGNESIUM OXIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"magnesium oxide","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"eldecalcitol","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ELDECALCITOL","company_name":"Chugai Pharmaceutical Co., Ltd","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"norethisterone","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micronor","generic_name":"norethisterone","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"GnRH receptors","drug_class":"Progestin","quality_score":63,"revenue":null,"mechanism":"ORIAHNN combines elagolix, which suppresses LH and FSH to reduce ovarian sex hormones, with estradiol and norethindrone acetate to mitigate side effects."},{"drug_id":"lasofoxifene","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fablyn","generic_name":"LASOFOXIFENE","company_name":"Dr. Friedrich Eberth Arzneimittel GmbH","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"lasofoxifene","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"colecalciferol","indication_name":"Glucocorticoid Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infuvite Adult","generic_name":"Colecalciferol","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"colecalciferol","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infuvite Adult","generic_name":"Colecalciferol","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"colecalciferol","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infuvite Adult","generic_name":"Colecalciferol","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"colecalciferol","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infuvite Adult","generic_name":"Colecalciferol","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"calcitonin-salmon-synthetic","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Miacalcin","generic_name":"calcitonin (salmon synthetic)","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"calcitonin receptors","drug_class":"Calcitonin [EPC]","quality_score":55,"revenue":null,"mechanism":"Calcitonin salmon acts as a calcitonin receptor agonist, primarily affecting bone, with additional effects on the kidneys and gastrointestinal tract."},{"drug_id":"incadronic-acid","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bisphonal","generic_name":"INCADRONIC ACID","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"incadronic acid","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"estradiol","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":69,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"cholecalciferol","indication_name":"Glucocorticoid Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin D3","generic_name":"cholecalciferol","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Sterol 26-hydroxylase, mitochondrial","drug_class":"Vitamin C [EPC]","quality_score":27,"revenue":null,"mechanism":null},{"drug_id":"cholecalciferol","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin D3","generic_name":"cholecalciferol","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Sterol 26-hydroxylase, mitochondrial","drug_class":"Vitamin C [EPC]","quality_score":27,"revenue":null,"mechanism":null},{"drug_id":"cholecalciferol","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin D3","generic_name":"cholecalciferol","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Sterol 26-hydroxylase, mitochondrial","drug_class":"Vitamin C [EPC]","quality_score":27,"revenue":null,"mechanism":null},{"drug_id":"cholecalciferol","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin D3","generic_name":"cholecalciferol","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Sterol 26-hydroxylase, mitochondrial","drug_class":"Vitamin C [EPC]","quality_score":27,"revenue":null,"mechanism":null},{"drug_id":"medroxyprogesterone","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Provera","generic_name":"medroxyprogesterone","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Progesterone receptor","drug_class":"Progestin","quality_score":null,"revenue":null,"mechanism":"Depo-Provera works by binding to the progesterone receptor in the body, which helps to regulate the menstrual cycle and prevent pregnancy."},{"drug_id":"ibandronic-acid","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Boniva","generic_name":"IBANDRONIC ACID","company_name":"Hoffmann La Roche","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"Bisphosphonate","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"calcium-lactate","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CALCIUM LACTATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"calcium lactate","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"calcium-lactate","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CALCIUM LACTATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"calcium lactate","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"ergocalciferol","indication_name":"Glucocorticoid Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drisdol","generic_name":"ERGOCALCIFEROL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","drug_class":"Provitamin D2 Compound [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"ergocalciferol","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drisdol","generic_name":"ERGOCALCIFEROL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","drug_class":"Provitamin D2 Compound [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"ergocalciferol","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drisdol","generic_name":"ERGOCALCIFEROL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","drug_class":"Provitamin D2 Compound [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"ergocalciferol","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drisdol","generic_name":"ERGOCALCIFEROL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","drug_class":"Provitamin D2 Compound [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"tibolone","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xyvion","generic_name":"TIBOLONE","company_name":"","drug_phase":"discontinued","molecular_target":"Sodium-dependent serotonin transporter","drug_class":"tibolone","quality_score":null,"revenue":null,"mechanism":"Xyvion works by binding to the sodium-dependent serotonin transporter, which helps regulate serotonin levels in the body."},{"drug_id":"neridronic-acid","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neridronate","generic_name":"NERIDRONIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"neridronic acid","quality_score":33,"revenue":null,"mechanism":"Neridronate works by inhibiting the enzyme Farnesyl pyrophosphate synthase, which plays a crucial role in bone resorption."},{"drug_id":"raloxifene","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evista","generic_name":"RALOXIFENE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"estrogen receptors","drug_class":"Estrogen Agonist/Antagonist","quality_score":75,"revenue":null,"mechanism":"Raloxifene binds to estrogen receptors, acting as an agonist in bone and an antagonist in uterine and breast tissues."},{"drug_id":"levonorgestrel","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jadelle","generic_name":"LEVONORGESTREL","company_name":"Fdn Consumer","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Progestin","quality_score":69,"revenue":null,"mechanism":"Jadelle works by binding to the progesterone receptor, which helps to prevent ovulation and thicken cervical mucus to prevent sperm from reaching the egg."},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Cultured Autologous Osteoblasts for the Treatment of Spinal Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"endometrin","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endometrin","generic_name":"progesterone","company_name":"Ferring","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"Progesterone [EPC]","quality_score":27,"revenue":null,"mechanism":null},{"drug_id":"calciferol","indication_name":"Glucocorticoid Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calciferol","company_name":"Department of Medical Services Ministry of Public Health of Thailand","drug_phase":"phase_1","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"calciferol","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calciferol","company_name":"Department of Medical Services Ministry of Public Health of Thailand","drug_phase":"phase_1","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"calciferol","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calciferol","company_name":"Department of Medical Services Ministry of Public Health of Thailand","drug_phase":"phase_1","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"calciferol","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calciferol","company_name":"Department of Medical Services Ministry of Public Health of Thailand","drug_phase":"phase_1","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"romosozumab","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evenity","generic_name":"romosozumab","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Sclerostin","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"romosozumab-aqqg","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"EVENITY","generic_name":"ROMOSOZUMAB-AQQG","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"Sclerostin","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"alendronate","indication_name":"Glucocorticoid Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"alendronate","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, EC 2.5.1.1, EC 2.5.1.10","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"alendronate","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"alendronate","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, EC 2.5.1.1, EC 2.5.1.10","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"alendronate","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"alendronate","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, EC 2.5.1.1, EC 2.5.1.10","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"alendronate","indication_name":"Prevention of Glucocorticoid-Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"alendronate","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, EC 2.5.1.1, EC 2.5.1.10","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"strontium","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Strontium Oxydatum","generic_name":"STRONTIUM","company_name":"Q Biomed","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"magnesium-citrate","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trimagnesium Dicitrate","generic_name":"MAGNESIUM CITRATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"magnesium citrate","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"magnesium-citrate","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trimagnesium Dicitrate","generic_name":"MAGNESIUM CITRATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"magnesium citrate","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"butedronic-acid","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BUTEDRONIC ACID","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"butedronic acid","quality_score":null,"revenue":null,"mechanism":"Butedronic acid works by inhibiting osteoclast activity, which are cells responsible for breaking down bone tissue."},{"drug_id":"ethinylestradiol","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ortho-Novum 10/11-21","generic_name":"Ethinylestradiol","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"estring","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"alendronic-acid","indication_name":"Glucocorticoid Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fosamax","generic_name":"ALENDRONIC ACID","company_name":"Merck And Co Inc","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"Vitamin D [EPC]","quality_score":63,"revenue":null,"mechanism":"Fosamax works by inhibiting bone resorption, allowing bone density to increase."},{"drug_id":"alendronic-acid","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fosamax","generic_name":"ALENDRONIC ACID","company_name":"Merck And Co Inc","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"Vitamin D [EPC]","quality_score":63,"revenue":null,"mechanism":"Fosamax works by inhibiting bone resorption, allowing bone density to increase."},{"drug_id":"alendronic-acid","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fosamax","generic_name":"ALENDRONIC ACID","company_name":"Merck And Co Inc","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"Vitamin D [EPC]","quality_score":63,"revenue":null,"mechanism":"Fosamax works by inhibiting bone resorption, allowing bone density to increase."},{"drug_id":"alendronic-acid","indication_name":"Prevention of Glucocorticoid-Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fosamax","generic_name":"ALENDRONIC ACID","company_name":"Merck And Co Inc","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"Vitamin D [EPC]","quality_score":63,"revenue":null,"mechanism":"Fosamax works by inhibiting bone resorption, allowing bone density to increase."},{"drug_id":"phytomenadione","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phytomenadione","company_name":"Instituto Mexicano del Seguro Social","drug_phase":"phase_2","molecular_target":"Alpha-synuclein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phytomenadione","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phytomenadione","company_name":"Instituto Mexicano del Seguro Social","drug_phase":"phase_2","molecular_target":"Alpha-synuclein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bazedoxifene","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"BAZEDOXIFENE","company_name":"Wyeth Pharms Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors (ER) α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE combines conjugated estrogens and bazedoxifene to activate estrogen receptors while reducing endometrial hyperplasia risk."},{"drug_id":"abaloparatide","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tymlos","generic_name":"ABALOPARATIDE","company_name":"Radius","drug_phase":"marketed","molecular_target":"Parathyroid hormone/parathyroid hormone-related peptide receptor","drug_class":"Parathyroid Hormone-Related Peptide Analog [EPC]","quality_score":75,"revenue":null,"mechanism":"Tymlos works by mimicking the action of parathyroid hormone to stimulate bone growth and increase bone density."},{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."},{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Prevention of postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."},{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Treatment of osteoporosis in postmenopausal women at high risk of fracture","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."},{"drug_id":"duavee","indication_name":"Prevention of postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"Bazedoxifene Acetate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Estrogen receptors (ER) α and β","drug_class":"Estrogen agonist/antagonist combination","quality_score":65,"revenue":null,"mechanism":"Pairs conjugated estrogens with bazedoxifene to bind and activate estrogen receptors α and β with tissue-specific effects."},{"drug_id":"calcium-citrate","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CALCIUM CITRATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"calcium citrate","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"calcium-citrate","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CALCIUM CITRATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"calcium citrate","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"zoledronic-acid","indication_name":"Glucocorticoid Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"zoledronic-acid","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"zoledronic-acid","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"zoledronic-acid","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"zoledronic-acid","indication_name":"Prevention of Glucocorticoid-Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"calcium-gluconate","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcium Gluconate","generic_name":"CALCIUM GLUCONATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"calcium gluconate","quality_score":60,"revenue":null,"mechanism":"Calcium gluconate increases serum ionized calcium levels when administered intravenously."},{"drug_id":"calcitonin","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Osteobios","generic_name":"CALCITONIN","company_name":"Sanofi Aventis Us","drug_phase":"marketed","molecular_target":"calcitonin receptor","drug_class":"Calcitonin [EPC]","quality_score":70,"revenue":null,"mechanism":"Calcitonin salmon acts as a calcitonin receptor agonist, primarily affecting bone, with additional effects on the kidneys and gastrointestinal tract."},{"drug_id":"ibandronate","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ibandronate","company_name":"University of California, San Francisco","drug_phase":"marketed","molecular_target":"Geranylgeranyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bonviva","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"bonviva","company_name":"Alvogen Korea","drug_phase":"phase_1","molecular_target":"Geranylgeranyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zometa","indication_name":"Glucocorticoid Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zometa","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zometa","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zometa","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zometa","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zometa","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zometa","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zometa","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zometa","indication_name":"Prevention of Glucocorticoid-Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zometa","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"neridronate","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neridronate","company_name":"Ente Ospedaliero Ospedali Galliera","drug_phase":"phase_3","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"progesteron","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Progesteron","company_name":"Minia University","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"raloxifen","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"raloxifen","company_name":"Organon and Co","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, HLA class I histocompatibility antigen, A-3 alpha chain, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoledronate","indication_name":"Glucocorticoid Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoledronate","company_name":"Children's Hospital Medical Center, Cincinnati","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoledronate","indication_name":"Hypogonadal Osteoporosis in Males","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoledronate","company_name":"Children's Hospital Medical Center, Cincinnati","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoledronate","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoledronate","company_name":"Children's Hospital Medical Center, Cincinnati","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoledronate","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoledronate","company_name":"Children's Hospital Medical Center, Cincinnati","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoledronate","indication_name":"Prevention of Glucocorticoid-Induced Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoledronate","company_name":"Children's Hospital Medical Center, Cincinnati","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phylloquinone","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Phylloquinone","company_name":"Guy's and St Thomas' NHS Foundation Trust","drug_phase":"phase_2","molecular_target":"Alpha-synuclein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phylloquinone","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Phylloquinone","company_name":"Guy's and St Thomas' NHS Foundation Trust","drug_phase":"phase_2","molecular_target":"Alpha-synuclein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Prevention of postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."},{"drug_id":"minodronate","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minodronate","company_name":"Peking University Third Hospital","drug_phase":"marketed","molecular_target":"Geranylgeranyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"calcitonin","indication_name":"Postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Osteobios","generic_name":"CALCITONIN","company_name":"Sanofi Aventis Us","drug_phase":"marketed","molecular_target":"calcitonin receptor","drug_class":"Calcitonin [EPC]","quality_score":70,"revenue":null,"mechanism":"Calcitonin salmon acts as a calcitonin receptor agonist, primarily affecting bone, with additional effects on the kidneys and gastrointestinal tract."},{"drug_id":"calcium-phosphate","indication_name":"Osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricalcium Phosphate","generic_name":"calcium phosphate","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"calcium phosphate","quality_score":19,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":98,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT02520362","title":"Denosumab Safety Assessment in Multiple Observational Databases","phase":"","overall_status":"COMPLETED","enrollment_count":517991,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05366621","title":"Post-fracture Medication and Mortality","phase":"","overall_status":"COMPLETED","enrollment_count":216155,"lead_sponsor_name":"National Cheng-Kung University Hospital","has_results":false},{"nct_id":"NCT03371433","title":"Soft Drinks and Osteoporosis in WHI Participants","phase":"","overall_status":"COMPLETED","enrollment_count":79885,"lead_sponsor_name":"University of California, San Diego","has_results":false},{"nct_id":"NCT05339425","title":"Chinese Osteoporotic Fracture Registration Network Platform","phase":"","overall_status":"COMPLETED","enrollment_count":50000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03699228","title":"China Health Big Data","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Beijing Jishuitan Hospital","has_results":false},{"nct_id":"NCT04974723","title":"Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women","phase":"","overall_status":"COMPLETED","enrollment_count":22054,"lead_sponsor_name":"Radius Health, Inc.","has_results":true},{"nct_id":"NCT06279078","title":"Long-term Effect of Steroid on Metabolic Diseases in Asthmatics","phase":"","overall_status":"COMPLETED","enrollment_count":19968,"lead_sponsor_name":"Ajou University School of Medicine","has_results":false},{"nct_id":"NCT04736693","title":"Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":18028,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT00529373","title":"A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":16071,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03916289","title":"A Tiered Management System of Osteoporosis in China","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT04879420","title":"Replication of the VERO Osteoporosis Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":12757,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT07100756","title":"Effectiveness of Implementation of Opportunistic AI-screening for Vertebral Fractures in Clinical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10500,"lead_sponsor_name":"University Hospital, Linkoeping","has_results":false},{"nct_id":"NCT01416194","title":"Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)","phase":"","overall_status":"COMPLETED","enrollment_count":10497,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07512453","title":"Study in Patients With Osteoporosis and Fragility Fractures to Estimate the Extent and Impact of Delayed Administration of Anti-fracture Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Azienda Ospedaliero, Universitaria Pisana","has_results":false},{"nct_id":"NCT00089791","title":"A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":7808,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT01575834","title":"Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":7180,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT01322568","title":"Research on Aging Project in Iceland: Second Stage","phase":"","overall_status":"COMPLETED","enrollment_count":5764,"lead_sponsor_name":"National Institute on Aging (NIA)","has_results":false},{"nct_id":"NCT05906147","title":"Health ImprOvement Program of Bone in China","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Second Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT05721157","title":"Osteoporotic Precisely Screening Using Chest Radiograph and Artificial Neural Network (OPSCAN)","phase":"NA","overall_status":"COMPLETED","enrollment_count":4912,"lead_sponsor_name":"National Defense Medical Center, Taiwan","has_results":false},{"nct_id":"NCT00523341","title":"Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4550,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07014306","title":"The Oswestry Metabolic BONE Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":4200,"lead_sponsor_name":"Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust","has_results":false},{"nct_id":"NCT06316544","title":"China Elderly Comorbidity Medical Database","phase":"","overall_status":"UNKNOWN","enrollment_count":4100,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT01631214","title":"Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4093,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04788290","title":"An Observational Study Assessing Effects in Patients With Combination Therapy With Raloxifene/Cholecalciferol","phase":"","overall_status":"COMPLETED","enrollment_count":3907,"lead_sponsor_name":"Hanmi Pharmaceutical Company Limited","has_results":false},{"nct_id":"NCT06304428","title":"Prevention of Injury in Skilled Nursing Facilities Through Optimizing Medications","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3780,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT04079868","title":"Models of Primary Osteoporosis Screening in Male Veterans","phase":"NA","overall_status":"COMPLETED","enrollment_count":3512,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT01793142","title":"Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice","phase":"","overall_status":"COMPLETED","enrollment_count":3430,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02089997","title":"Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)","phase":"","overall_status":"COMPLETED","enrollment_count":3304,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04947722","title":"The PREVENT Trial: a Pragmatic Cluster Randomized Controlled Trial of a Multifaceted Fracture Prevention Model for Long-term Care","phase":"NA","overall_status":"RECRUITING","enrollment_count":3060,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT04129671","title":"Rare Variation and Remote Gene Regulation of Osteoporosis Related Phenotypes in Han Chinesse","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07162168","title":"Automated Bone Age Estimation From Noncontrast Abdominal CT Using Deep Learning","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05614778","title":"Study to Investigate the Efficacy and Safety After Administration of Daewoong Zoledronic Acid for the Purpose of Treatment or Prevention of Osteoporosis","phase":"","overall_status":"COMPLETED","enrollment_count":2881,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT07487688","title":"Five-Year CT Follow-Up of Vertebral Fracture Risk Using Opportunistic Osteoporosis Screening","phase":"","overall_status":"COMPLETED","enrollment_count":2799,"lead_sponsor_name":"Technical University of Munich","has_results":false},{"nct_id":"NCT03924414","title":"Trial of Parkinson's And Zoledronic Acid","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2650,"lead_sponsor_name":"California Pacific Medical Center Research Institute","has_results":false},{"nct_id":"NCT06455085","title":"RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE","phase":"NA","overall_status":"RECRUITING","enrollment_count":2634,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT00172081","title":"TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2532,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT04796350","title":"RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures","phase":"NA","overall_status":"RECRUITING","enrollment_count":2400,"lead_sponsor_name":"AgNovos Healthcare, LLC","has_results":false},{"nct_id":"NCT05039216","title":"Biobank for Inflammatory Chronic Diseases and Osteoporosis","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT05473325","title":"Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Willows Health","has_results":false},{"nct_id":"NCT06915935","title":"Epidemiological Study of Osteoporosis in the Elderly Population of Shandong Province","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"The Second Hospital of Shandong University","has_results":false},{"nct_id":"NCT03401619","title":"Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT07474571","title":"Evaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06628388","title":"Nurse-led Primary Healthcare Intervention Model in Women's Health Management in Hong Kong","phase":"NA","overall_status":"RECRUITING","enrollment_count":1728,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT00172133","title":"Open Label Extension Study of PREOS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1683,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT01668589","title":"Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis","phase":"","overall_status":"COMPLETED","enrollment_count":1501,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06513442","title":"The Added Value of Bone Microstructure Assessment in the Management of Osteoporotic Bone","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}